|
|
局部晚期食管癌的新辅助治疗模式
|
Abstract:
我国是世界范围内的食管癌高发区域，由于缺乏早期的特异性症状，很多食管癌确诊时已发展为局部晚期。新辅助放化疗的出现为局部晚期食管癌患者提供了继单纯手术后又一治疗选择，虽然经历了褒贬不一的看法，但目前国内外大多数研究认为新辅助放化疗能有效增加食管癌的远期生存率及无病生存率，并提高了手术R0切除率、病理缓解率，因此逐渐成为局部晚期食管癌的标准化治疗方案。近年来免疫治疗及靶向治疗也开始加入食管癌新辅助治疗的队列中。本文就局部晚期食管癌的新辅助治疗方式进行综述。
China is a region with a high incidence of esophageal cancer worldwide, and due to the lack of early specific symptoms, many esophageal cancers have developed into locally advanced stages when di-agnosed. The emergence of neoadjuvant chemoradiotherapy provides another treatment option for patients with locally advanced esophageal cancer after surgery alone. Although it has experienced mixed opinions, most studies at home and abroad now believe that neoadjuvant chemoradiothera-py can effectively increase the long-term survival rate and disease-free survival rate of esophageal cancer, and improve the surgical R0 resection rate and pathological remission rate, so it is gradually becoming a standardized treatment option for locally advanced esophageal cancer. In recent years, immunotherapy and targeted therapy have also started to join the queue of neoadjuvant treatment for esophageal cancer. This article reviews the neoadjuvant treatment modalities for locally ad-vanced esophageal cancer.
| [1] | de Coa？a, Y.P., Choudhury, A. and Kiessling, R. (2015) Checkpoint Blockade for Cancer Therapy: Revitalizing a Suppressed Immune System. Trends in Molecular Medicine, 21, 482-491.
https://doi.org/10.1016/j.molmed.2015.05.005 |
| [2] | Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239 |
| [3] | Hong, M.H., Kim, H.R., Park, S.Y., et al. (2019) A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC). Journal of Clinical Oncology, 37, 4027.
https://doi.org/10.1200/JCO.2019.37.15_suppl.4027 |
| [4] | Li, C., Zhao, S., Zheng, Y., et al. (2021) Preoperative Pembrolizumab Combined with Chemoradiotherapy for Oesophageal Squamous Cell Carcinoma (PALACE-1). Europe-an Journal of Cancer, 144, 232-241.
https://doi.org/10.1016/j.ejca.2020.11.039 |
| [5] | Kelly, R.J., Smith, K.N., Anagnostou, V., et al. (2019) Neoadjuvant Nivolumab plus Concurrent Chemoradiation in Stage II/III Esophageal/Gastroesophageal Junction Cancer. Journal of Clinical Oncology, 37, 142.
https://doi.org/10.1200/JCO.2019.37.4_suppl.142 |
| [6] | Ge, F., Huo, Z., Cai, X., et al. (2022) Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined with Chemotherapy for Patients with Resectable Esophageal Cancer: A Systematic Review and Meta-Analysis. JAMA Network Open, 5, e2239778. https://doi.org/10.1001/jamanetworkopen.2022.39778 |
| [7] | Okines, A.F.C., Langley, R.E., Thompson, L.C., et al. (2013) Bevacizumab with Peri-Operative Epirubicin, Cisplatin and Capecitabine (ECX) in Localised Gastro-Oesophageal Adenocarcinoma: A Safety Report. Annals of Oncology, 24, 702-709. https://doi.org/10.1093/annonc/mds533 |
| [8] | Lockhart, A.C., Reed, C.E., Decker, P.A., et al. (2014) Phase II Study of Neoadjuvant Therapy with Docetaxel, Cisplatin, Panitumumab, and Radiation Therapy Followed by Surgery in Pa-tients with Locally Advanced Adenocarcinoma of the Distal Esophagus (ACOSOG Z4051). Annals of Oncology, 25, 1039-1044. https://doi.org/10.1093/annonc/mdu091 |
| [9] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [10] | Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338 |
| [11] | Schlag, P.M. (1992) Randomized Trial of Preoperative Chemotherapy for Squamous Cell Cancer of the Esophagus. Archives of Sur-gery, 127, 1446-1450. https://doi.org/10.1001/archsurg.1992.01420120080015 |
| [12] | Apinop, C., Puttisak, P. and Preecha, N. (1994) A Prospective Study of Combined Therapy in Esophageal Cancer. Hepato-Gastroenterology, 41, 391-393. |
| [13] | Prise, E.L., Etienne, P.L., Meunier, B., et al. (1994) A Randomized Study of Chemotherapy, Radiation Therapy, and Surgery versus Surgery for Localized Squamous Cell Carcinoma of the Esophagus. Cancer, 73, 1779-1784.
https://doi.org/10.1002/1097-0142(19940401)73:7<1779::AID-CNCR2820730702>3.0.CO;2-T |
| [14] | Walsh, T.N., Noonan, N., Hollywood, D., et al. (1996) A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocar-cinoma. New England Journal of Medicine, 335, 462-467.
https://doi.org/10.1056/NEJM199608153350702 |
| [15] | Vogel, S.B., Mendenhall, W.M., Sombeck, M.D., et al. (1995) Downstaging of Esophageal Cancer after Preoperative Radiation and Chemotherapy. Annals of Surgery, 221, 685-693. https://doi.org/10.1097/00000658-199506000-00008 |
| [16] | Shah, M.A., Kennedy, E.B., Catenacci, D.V., et al. (2020) Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 38, 2677-2694. https://doi.org/10.1200/JCO.20.00866 |
| [17] | Lordick, F., Mariette, C., Haustermans, K., et al. (2016) Oesophageal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 27, v50-v57. https://doi.org/10.1093/annonc/mdw329 |
| [18] | Kitagawa, Y., Uno, T., Oyama, T., et al. (2019) Esoph-ageal Cancer Practice Guidelines 2017 Edited by the Japan Esophageal Society: Part 1. Esophagus, 16, 1-24. https://doi.org/10.1007/s10388-018-0641-9 |
| [19] | Li, J. and Ma, S. (2021) History and Current Situation of Neoad-juvant Treatment for Locally Advanced Esophageal Cancer. Thoracic Cancer, 12, 2293-2299. https://doi.org/10.1111/1759-7714.14069 |
| [20] | Kelsen, D.P., Ginsberg, R., Pajak, T.F., et al. (1998) Chemotherapy Followed by Surgery Compared with Surgery Alone for localized Esophageal Cancer. New England Journal of Medicine, 339, 1979-1984.
https://doi.org/10.1056/NEJM199812313392704 |
| [21] | Working M R C O C (2002) Surgical Resection with or without Preoperative Chemotherapy in Oesophageal Cancer: A Randomised Controlled Trial. The Lancet, 359, 1727-1733. https://doi.org/10.1016/S0140-6736(02)08651-8 |
| [22] | Thirion, P.G., Michiels, S., Le Maitre, A., et al. (2007) Individual Patient Data-Based Meta-Analysis Assessing Pre-Operative Chemotherapy in Resectable Oesophageal Carcinoma. Journal of Clinical Oncology, 25, 4512-4512.
https://doi.org/10.1200/jco.2007.25.18_suppl.4512 |
| [23] | Kelsen, D.P., Winter, K.A., Gunderson, L.L., et al. (2007) Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemo-therapy Followed by Surgery Compared with Surgery Alone for Esophageal Cancer. Journal of Clinical Oncology, 25, 3719-3725. https://doi.org/10.1200/JCO.2006.10.4760 |
| [24] | Allum, W.H., Stenning, S.P., Bancewicz, J., et al. (2009) Long-Term Results of a Randomized Trial of Surgery with or without Preoperative Chemotherapy in Esophageal Cancer. Journal of Clinical Oncology, 27, 5062-5067.
https://doi.org/10.1200/JCO.2009.22.2083 |
| [25] | Ando, N., Kato, H., Igaki, H., et al. (2012) A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). Annals of Surgical Oncol-ogy, 19, 68-74.
https://doi.org/10.1245/s10434-011-2049-9 |
| [26] | 郑晓东, 张卫民, 侯建彬. 新辅助化疗联合微创手术治疗局部进展期食管癌安全性及远期疗效分析[J]. 中国现代医药杂志, 2019, 21(7): 39-42. |
| [27] | 何金龙, 王保收, 朱岩. 新辅助化疗联合手术治疗食管癌的临床疗效及对患者预后的影响[J]. 癌症进展, 2022, 20(16): 1687-1689. |
| [28] | 华胸怀, 魏秀峰, 史可峰, 等. 术前新辅助化疗对食管鳞癌患者胸腹腔镜手术及预后的影响[J]. 中华胸部外科电子杂志, 2019, 6(2): 91-96. |
| [29] | van Hagen, P., Hulshof, M., Van Lanschot, J.J.B., et al. (2012) Preoperative Chemoradi-otherapy for Esophageal or Junctional Cancer. New England Journal of Medicine, 366, 2074-2084. https://doi.org/10.1056/NEJMoa1112088 |
| [30] | Eyck, B.M., van Lanschot, J.J.B., Hulshof, M., et al. (2021) Ten-Year Outcome of Neoadjuvant Chemoradiotherapy plus Surgery for Esophageal Cancer: The Randomized Con-trolled CROSS Trial. Journal of Clinical Oncology, 39, 1995-2004. https://doi.org/10.1200/JCO.20.03614 |
| [31] | Yang, H., Liu, H., Chen, Y., et al. (2018) Neoadjuvant Chemoradio-therapy Followed by Surgery versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. Journal of Clinical Oncology, 36, 2796-2803.
https://doi.org/10.1200/JCO.2018.79.1483 |
| [32] | Mariette, C., Dahan, L., Mornex, F., et al. (2014) Surgery Alone versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901. Journal of Clinical Oncology, 32, 2416-2422. https://doi.org/10.1200/JCO.2013.53.6532 |
| [33] | Yang, H., Liu, H., Chen, Y., et al. (2021) Long-Term Efficacy of Neoadjuvant Chemoradiotherapy plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carci-noma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surgery, 156, 721-729. https://doi.org/10.1001/jamasurg.2021.2373 |
| [34] | 程良, 高薇, 田东, 等. 进展期食管鳞癌新辅助放化疗与新辅助化疗的分析[J]. 中华放射肿瘤学杂志, 2021, 30(1): 34-41. |
| [35] | Sjoquist, K.M., Burmeister, B.H., Smithers, B.M., et al. (2011) Survival after Neoadjuvant Chemotherapy or Chemoradiotherapy for Resectable Oesophageal Carcinoma: An Updated Meta-Analysis. The Lancet Oncology, 12, 681-692.
https://doi.org/10.1016/S1470-2045(11)70142-5 |
| [36] | Wang, H., Tang, H., Fang, Y., et al. (2021) Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy after Neoadjuvant Chemoradiotherapy vs Ne-oadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Surgery, 156, 444-451.
https://doi.org/10.1001/jamasurg.2021.0133 |
| [37] | Ruhstaller, T., Thuss-Patience, P., Hayoz, S., et al. (2018) Neoadjuvant Chemotherapy Followed by Chemoradiation and Surgery with and without Cetuximab in Patients with Re-sectable Esophageal Cancer: A Randomized, Open-Label, Phase III Trial (SAKK 75/08). Annals of Oncology, 29, 1386-1393. https://doi.org/10.1093/annonc/mdy105 |
| [38] | Nakamura, K., Kato, K., Igaki, H., et al. (2013) Three-Arm Phase III Trial Comparing Cisplatin plus 5-FU (CF) versus Docetaxel, Cisplatin plus 5-FU (DCF) versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT study). Japanese Journal of Clinical Oncology, 43, 752-755.
https://doi.org/10.1093/jjco/hyt061 |
